Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, Life Science Research Center, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan 421001, China; Laboratory of Clinical Anatomy, University of South China, Hengyang 421001, China.
Department of Metabolism & Endocrinology of the First Affiliated Hospital, University of South China, Hengyang 421001, China.
Atherosclerosis. 2015 May;240(1):80-9. doi: 10.1016/j.atherosclerosis.2015.02.044. Epub 2015 Feb 24.
Diosgenin (Dgn), a structural analogue of cholesterol, has been reported to have the hypolipidemic and antiatherogenic properties, but the underlying mechanisms are not fully understood. Given the key roles of macrophages in cholesterol metabolism and atherogenesis, it is critical to investigate macrophage cholesterol efflux and development of atherosclerotic lesion after Dgn treatment.
This study was designed to evaluate the potential effects of Dgn on macrophage cholesterol metabolism and the development of aortic atherosclerosis, and to explore its underlying mechanisms.
Dgn significantly up-regulated the expression of ATP-binding cassette transporter A1 (ABCA1) protein, but didn't affect liver X receptor α levels in foam cells derived from human THP-1 macrophages and mouse peritoneal macrophages (MPMs) as determined by western blotting. The miR-19b levels were markedly down-regulated in Dgn-treated THP-1 macrophages/MPM-derived foam cells. Cholesterol transport assays revealed that treatment with Dgn alone or together with miR-19b inhibitor notably enhanced ABCA1-dependent cholesterol efflux, resulting in the reduced levels of total cholesterol, free cholesterol and cholesterol ester as determined by high-performance liquid chromatography. The fecal 3H-sterol originating from cholesterol-laden MPMs was increased in apolipoprotein E knockout mice treated with Dgn or both Dgn and antagomiR-19b. Treatment with Dgn alone or together with antagomiR-19b elevated plasma high-density lipoprotein levels, but reduced plasma low-density lipoprotein levels. Accordingly, aortic lipid deposition and plaque area were reduced, and collagen content and ABCA1 expression were increased in mice treated with Dgn alone or together with antagomiR-19b. However, miR-19b overexpression abrogated the lipid-lowering and atheroprotective effects induced by Dgn.
The present study demonstrates that Dgn enhances ABCA1-dependent cholesterol efflux and inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression.
本研究旨在评估薯蓣皂苷元(Dgn)对巨噬细胞胆固醇代谢和主动脉粥样硬化形成的潜在作用,并探讨其潜在机制。
Western blot 结果显示,Dgn 可显著上调人 THP-1 巨噬细胞和小鼠腹腔巨噬细胞(MPM)源性泡沫细胞中 ATP 结合盒转运体 A1(ABCA1)蛋白的表达,但对肝 X 受体α水平无影响。Dgn 处理的 THP-1 巨噬细胞/MPM 源性泡沫细胞中 miR-19b 水平明显下调。胆固醇转运实验显示,Dgn 单独或与 miR-19b 抑制剂联合处理可显著增强 ABCA1 依赖性胆固醇流出,从而降低高效液相色谱法测定的总胆固醇、游离胆固醇和胆固醇酯水平。载脂蛋白 E 敲除小鼠给予 Dgn 或 Dgn 加 antagomiR-19b 处理后,粪便 3H-胆固醇水平升高。Dgn 单独或与 antagomiR-19b 联合处理可升高血浆高密度脂蛋白水平,降低血浆低密度脂蛋白水平。因此,Dgn 单独或与 antagomiR-19b 联合处理可减少小鼠主动脉脂质沉积和斑块面积,增加胶原含量和 ABCA1 表达。然而,miR-19b 过表达可消除 Dgn 诱导的降脂和抗动脉粥样硬化作用。
本研究表明,Dgn 通过抑制巨噬细胞 miR-19b 表达增强 ABCA1 依赖性胆固醇流出,抑制主动脉粥样硬化进展。